ChatGPT, the Biggest Thing Since the Internet.
Gary and Tanner talk about racking up 2.5 million views on Instagram Reels, how ChatGPT is influencing content creation.
https://youtu.be/bnRHb7DtUsw
The Retreat of the Amateur Investors (WSJ)
A pandemic boom attracted scores of Americans seeking gains. Now that some are backing away, the markets risk losing a key support.
Amateur trader Omar...
Revive Therapeutics (RVVTF) Advancing MDMA Thermal Patch.
Two News Reports Related to Revives Upcoming Microneedle Patch Technology
While we are still laser focused on Revive having a successful meeting with the FDA...
SILO Pharma (SILO) Gains 53%
For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun.
Silo Pharma Gains 53% Intraday on Patent (Ketamine) Related News
Our opinion...
Citius Pharma (CTXR). Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024
Uptick in patient recruitment for Mino-Lok® Phase 3 trial
Halo-Lido Phase 2b trial nearing completion
CRANFORD,...
Silo Pharma (SILO) $2.67 Announces $1 Million Stock Buyback.
Yes it doesn't sound like a lot of money on the surface. But the stock is so grossly undervalued (in our opinion) and there...
Three That Doubled, Three More That May Double.
Ardelyx $3.00 (ARDX) Gains 117%, Provention Bio $8.75 (PRVB) Gains 134%, and PharmaTher (PHRRF) up 154%. Blue Skies Ahead - For All Three.
Revive Therapeutics...
Initiating Coverage on Society Pass (SOPA).
Institutional Analyst: Society Pass (Nasdaq: SOPA) - Acquiring and Incubating Startups in the Heart of the Asian Silicon Valley
NEW YORK, NY, Jan. 24, 2023 (GLOBE...
Society Pass (SOPA) Research Reports
RESEARCH REPORT ARCHIVE
December 27th, 2023. Litchfield Hills Research - $4.00 Price Target.
NEW YORK, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Society Pass Inc. (Nasdaq: SOPA) (“SoPa” or...
Adding Society Pass (SOPA) $0.96 to the Watch List
Amazing Fast Grower, in the Asian Silicon Valley.
After a wildly successful IPO debut and subsequent tumble, Society Pass (SOPA) in our opinion is...